Bench, bath and beyond

Transform your apartment into a yeast lab, and have fun doing it!

Grad Admissions Blog | Veda K.
October 22, 2020
One of the very first lessons you learn in microbiology is that while countless things can – and will – go wrong, you can almost always count on your microbes to grow. There is some strange comfort in knowing that what looks like clear liquid today will reveal countless gleaming colonies smiling up at you from your petri dish tomorrow. This radical assurance of growth transforms the many tedious tasks of lab work into an almost meditative experience. Pouring, plating, streaking — these could easily be yoga poses in the clinically sterile studio of a BSL-2 lab[1].

When the pandemic-that-shall-not-be-named abruptly separated me from my work this March, I threatened to bring the lab home. Unsurprisingly, my roommates were far from enthused at the idea of me culturing human pathogens in our garage. Somewhere in-between trying to bribe them with beer and baked goods I realized I could turn my scientific focus on an organism far more delicious than MRSA[2]: yeast!

Yeast, the tiny organism so miraculous that it was known as “godisgoode” in the days before microscopes were invented, is behind the magical transformations that give us beer, wine, sourdough, doughnuts, kombucha — you name it. In our technological times, it is tempting to relegate the study of microbes to sterile, fluorescently-lit, strictly controlled labs where the genetically engineered organisms you order off the internet live pampered lives. In quarantine in my own home, I re-discovered a centuries-old truth: yeast will appear and grow anywhere. Like any good pet, yeast are largely well-behaved and will sit, stand, and shake your hand on command. Disclaimer: they may also bubble over and stain your carpet in unsavory ways.

With a bit of intuition and a lot of patience, you too can transform any apartment into a lab to grow your pet yeast in!

The kitchen: your new bench

Sourdough: needy but delicious

Growing your own sourdough starter is a relatively low-effort process that is not only ridiculously easy, it also lends you serious kitchen clout. All you need to get started are flour, water, and the right temperature. Combine the flour and water in equal quantities in a container with quite a bit of headspace. “Feed” your starter once a day by replacing half of it by weight with a fresh water-flour mixture. Grow your starter at 68-75F. In the cold of the winter, yeast will take longer to grow and consume the complex nutrients in flour. In the summer, your starter may be so active it requires “feeding” twice a day!

 A young starter with “hooch” on top

As the complex community develops in your starter, it will go from being watery (the liquid on top is actually called “hooch”, if that is any indication of its actual nature) and frankly pretty stinky to bubbly and aromatic. Your nose and eyes are your best tools for judging what bugs are living in your starter (move over, Illumina[3]!). Fuzzy and white? Probably mould! Orange and cheesey? Serratia marcescens is likely the culprit. Simply use a clean spoon to remove these offending species. The wonderful magic of your starter is that, as a living community of wild yeasts and bacteria, it will eventually fend off nastier invaders and reach a set-point of well-behaved yeast. Patience is crucial! Keep feeding, and believe in “godisgoode”.

As a microbiologist, I must admit that the process of developing a working starter far outweighed the actual bread-baking process. For those of you who are excited about baking – the starter can be used for pancakes, doughnuts, muffins, cake, almost any dessert that uses dry active yeast. When you need a break from your prolific baking streak, simply pop your starter in the freezer and it’ll be ready for the next time you get hungry!

Beer: hurry up and wait

Over our many weeks in confinement, my roommates and I have been refining our beer-tasting palates by attending Lamplighter Brewery’s virtual tasting events. The wonderful folks at lamp gave me my first introduction to how beer is made and, eager to fill my weekends with more than just existential dread, I decided to venture into brewing.

To be completely honest, I’d also been missing those $6 pitchers of High Life at the Muddy (the Muddy Charles Pub, a campus highlight).

Like baking, brewing is a process that has engendered a cult-following. Homebrewers take their craft seriously, and you can find countless blog posts and youtube videos describing everything from sanitization techniques to pitch rates (how much yeast goes in) to heated debates on hop flavor profiles. To an MIT grad student, drinking from this “firehose” of information should feel almost comfortable, if you can withstand the flashbacks to 7.51 (principles of biochemical analysis). The trick, I’ve learned, is to dive in headfirst and take in specific pieces of information only as needed.

Brewing requires a little more investment than baking. The equipment you need will likely not be lying around the house, and unfortunately cannot be repurposed for much if you find that brewing isn’t quite your thing. The good news is that there are several companies selling pre-assembled “kits” to get you started on your boozy journey. After doing some research of my own, and soliciting advice from my homebrewer friends, I went with an IPA kit that included most of the hardware I’d need.

My first (and only, so far) brew day was a 6-hour process. Like any experiment in the lab, I anxiously sanitized, scrubbed, stirred, heated and cooled alternately. The day after, I realized my hyper-aware level of caution had been superfluous – my yeast were happily bubbling away in their preferred temperature range of 68F-75F. Little did I know that they’d still be bubbling away two weeks later at 91F (!!), thanks to the heat of a Boston summer and a failed condenser in our central AC.

The garage: your new incubator / engineering lab

Once your beer has been brewed, it needs to ferment in a cool, dark place for two weeks. The only cool, dark place in our now very hot apartment is our garage, which has been taken over by my MechE roomie (hey Annie!) Annie, not constrained by a study of deadly bacteria, was uninhibited in her assembly of a mini-engineering lab in our garage, even having equipment sent directly to our apartment! My yeast and fermenting beer join her assorted selection of wires in filling the void in our hearts normally filled by our labs.

Sourdough starter fed and beer bottled, all that is left to do is wait. In between waiting for bread and booze, I like to sneak in some studying for my upcoming qualifying exams!

As we become ever more intimately acquainted with our homes and the yeast that inhabit them, I highly encourage you to experience the magic of micro-organismal life for yourself. Biting into that first slice of bread or taking your first sip of home-brewed beer is a fulfilling reminder that, but for the pardoning mercy of an only 99.99% effective clorox wipe, our sterile world would be dull and flat. Grant yourself a moment to breathe and celebrate the 0.01% of microbes that make our world wonderful — you’ll be back in the lab in no time!

[1] Biosafety level 2 (BSL-2)refers to  laboratories that work with biological agents that pose a moderate health hazard

[2] Methicillin-Resistant Staphylococcus Aureus (MRSA) is a form of antibiotic resistant bacteria that causes infections

[3] Illumina is a DNA sequencing company that is well known for its technology

Course 7 Alums Named to 2020 Fortune 40 Under 40 List
Julie Fox | Slice of MIT
October 21, 2020

To mark a year of “monumental change,” the editors of Fortune say they decided to upend the publication’s annual “40 Under 40” feature, forgoing a single list and instead highlighting 40 influential people in each of five categories: finance, technology, health care, government and politics, and media and entertainment.

Read on to meet the six MIT alumni who made this year’s list. And learn more about them and the other honorees on the Fortune 40 Under 40 website. (All images via Fortune.)

Fortune 2020 “40 Under 40”: MIT Alumni

Amir Barsoum MBA ’20 (Health Care)

Founder and CEO, Vezeeta

“A Zocdoc-like platform…to empower people with information about health providers that has been traditionally hard to find in the region.” Read more: Fortune.

Suelin Chen ’03, SM ’07, PhD ’10 (Health Care)

CEO, Cake

“A web-based service that helps users plan for their end-of-life goals and wishes.” Read more: Fortune.

Jason Kelly ’03, PhD ’08 (Health Care)

Cofounder and CEO, Ginkgo Bioworks

“The company’s early investment in automation made it uniquely well equipped to tackle Covid-19…building a facility capable of testing 100,000 samples a day.” More: Fortune.

Akshay Naheta SM ’04 (Finance)

Senior vice president of investments, SoftBank Group

“Helping implement the [Japanese telecom] company’s multibillion-dollar plan to win back shareholder confidence.” More: Fortune.

Kartik Ramamoorthi PhD ’14 (Health Care)

Cofounder and CEO, Encoded Therapeutics

“An inventor and provisional patent holder with more than a dash of scientist and entrepreneurial spirit.” More: Fortune.

Rebecca Elizabeth Lipon Weekly ’03 (Technology)

Senior director of cloud business strategy and platform enabling, Intel Corporation

“Helps craft products and features to appeal to Intel’s cloud provider customers amid fierce competition from AMD and Nvidia.” More: Fortune.

Cancer researchers collaborate, target DNA damage repair pathways for cancer therapy

MIT researchers find blocking the expressions of the genes XPA and MK2 enhances the tumor-shrinking effects of platinum-based chemotherapies in p53-mutated cancers.

Koch Institute
October 2, 2020

Cancer therapies that target specific molecular defects arising from mutations in tumor cells are currently the focus of much anticancer drug development. However, due to the absence of good targets and to the genetic variation in tumors, platinum-based chemotherapies are still the mainstay in the treatment of many cancers, including those that have a mutated version of the tumor suppressor gene p53. P53 is mutated in a majority of cancers, which enables tumor cells to develop resistance to platinum-based chemotherapies. But these defects can still be exploited to selectively target tumor cells by targeting a second gene to take down the tumor cell, leveraging a phenomenon known as synthetic lethality.

Focused on understanding and targeting cell signaling in cancer, the laboratory of Michael Yaffe, the David H. Koch Professor Science and director of the MIT Center for Precision Cancer Medicine, seeks to identify pathways that are synthetic lethal with each other, and to develop therapeutic strategies that capitalize on that relationship. His group has already identified MK2 as a key signaling pathway in cancer and a partner to p53 in a synthetic lethal combination.

Now, working with a team of fellow researchers at MIT’s Koch Institute for Integrative Cancer Research, Yaffe’s lab added a new target, the gene XPA, to the combination. Appearing in Nature Communications, the work demonstrates the potential of “augmented synthetic lethality,” where depletion of a third gene product enhances a combination of targets already known to show synthetic lethality. Their work not only demonstrates the effectiveness of teaming up cancer targets, but also of the collaborative teamwork for which the Koch Institute is known.

P53 serves two functions: first, to give cells time to repair DNA damage by pausing cell division, and second, to induce cell death if DNA damage is too severe. Platinum-based chemotherapies work by inducing enough DNA damage to initiate the cell’s self-destruct mechanism. In their previous work, the Yaffe lab found that when cancer cells lose p53, they can re-wire their signaling circuitry to recruit MK2 as a backup pathway. However, MK2 only restores the ability to orchestrate DNA damage repair, but not to initiate cell death.

The Yaffe group reasoned that targeting MK2, which is only recruited when p53 function is absent, would be a unique way to create a synthetic lethality that specifically kills p53-defective tumors, by blocking their ability to coordinate DNA repair after chemotherapy. Indeed, the Yaffe Lab was able to show in pre-clinical models of non-small cell lung cancer tumors with mutations in p53, that silencing MK2 in combination with chemotherapy treatment caused the tumors to shrink significantly.

Although promising, MK2 has proven difficult to drug. Attempts to create target-specific, clinically viable small-molecule MK2 inhibitors have so far been unsuccessful. Researchers led by co-lead author Yi Wen Kong, then a postdoc in the Yaffe lab, have been exploring the use of RNA interference (siRNA) to stop expression of the MK2 gene, but siRNA’s tendency to degrade rapidly in the body presents new challenges.

Enter the potential of nanomaterials, and a team of nanotechnology experts in the laboratory of Paula Hammond, the David H. Koch Professor of Engineering, head of the MIT Department of Chemical Engineering, and the Yaffe group’s upstairs neighbor. There, Kong found a willing collaborator in then-postdoc Erik Dreaden, whose team had developed a delivery vehicle known as a nanoplex to protect siRNA until it gets to a cancer cell. In studies of non-small cell lung cancer models where mice were given the MK2-targeting nanocomplexes and standard chemotherapy, the combination clearly enhanced tumor cell response to chemotherapy. However, the overall increase in survival was significant, but relatively modest.

Meanwhile, Kong had identified XPA, a key protein involved in another DNA repair pathway called NER, as a potential addition to the MK2-p53 synthetic lethal combination. As with MK2, efforts to target XPA using traditional small-molecule drugs have not yet proven successful, and RNA interference emerged as the team’s tool of choice. The flexible and highly controllable nature of the Hammond group’s nanomaterials assembly technologies allowed Dreaden to incorporate siRNAs against both XPA and MK2 into the nanocomplexes.

Kong and Dreaden tested these dual-targeted nanocomplexes against established tumors in an immunocompetent, aggressive lung cancer model developed in collaboration between the laboratories of professor of biology Michael Hemann and Koch Institute Director Tyler Jacks. They let the tumors grow even larger before treatment than they had in their previous study, thus raising the bar for therapeutic intervention.

Tumors in mice treated with the dual-targeted nanocomplexes and chemotherapy were reduced by up to 20-fold over chemotherapy alone, and similarly improved over single-target nanocomplexes and chemotherapy. Mice treated with this regimen survived three times longer than with chemotherapy alone, and much longer than mice receiving nanocomplexes targeting MK2 or XPA alone.

Overall, these data demonstrate that identification and therapeutic targeting of augmented synthetic lethal relationships — in this case between p53, MK2 and XPA — can produce a safe and highly effective cancer therapy by re-wiring multiple DNA damage response pathways, the systemic inhibition of which may otherwise be toxic.

The nanocomplexes are modular and can be adapted to carry other siRNA combinations or for use against other cancers in which this augmented synthetic lethality combination is relevant. Beyond application in lung cancer, the researchers — including Kong, who is now a research scientist at the Koch Institute, and Dreaden, who is now an assistant professor at Georgia Tech and Emory School of Medicine — are working to test this strategy for use against ovarian and other cancers.

Additional collaborations and contributions were made to this project by the laboratories of Koch Institute members Stephen Lippard and Omer Yilmaz, the Eisen and Chang Career Development Professor.

This work was supported in part by a Mazumdar-Shaw International Oncology Fellowship, a postdoctoral fellowship from the S. Leslie Misrock (1949) Frontier Fund for Cancer Nanotechnology, and by the Charles and Marjorie Holloway Foundation, the Ovarian Cancer Research Foundation, and the Breast Cancer Alliance.

3 Questions: Nancy Hopkins on improving gender equality in academia

Molecular biologist and professor emerita advocates for more inclusive science and advises how to get there.

Raleigh McElvery | Department of Biology
September 30, 2020

Over the course of her exceptional career, Amgen Professor of Biology Emerita Nancy Hopkins has overturned assumptions and defied expectations at the lab bench and beyond. After arriving at MIT in 1973, she set to work mapping RNA tumor virus genes, before switching her focus and pioneering zebrafish as a model system to probe vertebrate development and cancer.

Her experiences in male-dominated fields and institutions led her to catalyze an investigation that evolved into the groundbreaking 1999 public report on the status of women at MIT. These findings spurred nine universities, including MIT, to establish an ongoing effort to improve gender equity. A recent documentary, Picture a Scientist,chronicles this watershed report and spotlights researchers like Hopkins who champion underrepresented voices. She sat down to discuss what has changed for women in academia in the last two decades — and what hasn’t.

Q: How has the situation for women in science evolved since the landmark 1999 report?

A: It’s hard today to remember just how radical the 1999 report was at the time. I read it now and think, ‘What was so radical about that?’

The report documented that women joined the faculty believing that only greater family responsibilities might impede their success relative to male colleagues. But, as they progressed through tenure, many were marginalized and undervalued. Data showed this resulted in women having fewer institutional resources and rewards for their research, and in their exclusion from important professional opportunities. When the study began, only 8% of the science faculty were women.

Former MIT Dean of Science Robert Birgeneau addressed inequities on a case-by-case basis, adjusting salaries, space, and resources. He recruited women aggressively, quickly increasing the number of women School of Science faculty by 50%.

When the report became public, the overwhelming public reaction made clear that it described problems that were epidemic among women in science, technology, engineering, and mathematics (STEM). Former MIT President Chuck Vest and Provost Bob Brown addressed gender bias for all of MIT and “institutionalized” solutions. They established committees in the five MIT schools to ensure that inequities were promptly addressed and hiring policies were fair; rewrote family leave policies with input from women faculty; built day care facilities on campus; and recruited women faculty to high-level administrative positions.

Today, we realize that the MIT report elucidated two underappreciated forms of bias: “institutional bias” resulting from a system designed for a man with a wife at home; and “unconscious or implicit gender bias.” Voluminous research by psychologists has documented the latter, showing that identical work is undervalued if people believe it was done by a woman. Refusal to acknowledge unconscious gender bias today is akin to denying the world is round.

Q: What do you hope people will take away from the “Picture a Scientist” film?

A: I hope people will better understand why women are underrepresented in science, and women of color particularly so. The film does a terrific job of portraying the range of destructive behaviors that collectively explain the question, “Why so few?” The movie also focuses on the courage it takes for young women scientists to expose these problems.

I hope people will agree that, despite all the progress for women in my generation, as the bombshell report from the National Academy of Sciences documented in 2018, sexual harassment and gender discrimination persist and still require constant attention. It remains a challenge to identify, attract, and retain the best STEM talent. And, as the movie points out, it’s critical to do so.

The producers have received an unprecedented number of requests to show the documentary in institutes, universities, and companies, confirming that underrepresentation remains a widespread and pressing issue.

Q: Where do we go from here? How can academia better support underrepresented groups in science moving forward?

A: People often say you have to “change the culture,” but what does that really mean? You have to do what MIT did: look at the data; make corrections, including policy changes if necessary; continue to track the data to see if the policies work; and repeat as needed. Second, as the National Academies report points out, you must reward administrators who create a diverse workplace. Top talent is distributed among diverse groups. You can only be the best by being diverse.

But how do you change the behavior of individual faculty? Years ago, President Vest told me, “Nancy, anything I can measure I can fix, but I don’t know how to fix marginalization.” His comment was prescient. We’re pretty good at fixing things we can measure. But not at retraining our own unconscious biases: preference for working with people who look just like us; and unexamined, biased assumptions about people different from us. But psychologists tell us all we have to do is ‘change the world and our biases will change along with it.’  Furthermore, they now have methods to measure change in our biases.

I championed this cause because I believe being a scientist is the greatest job there is. I want anyone with this passion to be able to be a scientist. I’m grateful I got to see change first hand. I just wish the change was faster, so young women like Jane Willenbring and Raychelle Burks in the movie can just be scientists.

Ibrahim Cissé, Ruth Lehmann, and Silvi Rouskin awarded 2021 Vilcek Prize

Prize recognizes contributions to biomedical research made by immigrant scientists.

Raleigh McElvery | Sandi Miller | Department of Biology | Department of Physics
September 25, 2020

Associate professor of physics and biology Ibrahim Cissé, professor of biology and Whitehead Institute Director Ruth Lehmann, and Andria and Paul Heafy Whitehead Fellow Silvi Rouskin have been awarded 2021 Vilcek Prizes. The Vilcek Foundation was established in 2000 by Jan and Marica Vilcek, who emigrated from the former Czechoslovakia. Their prizes honor the outstanding contributions of immigrants in the sciences and the arts. Prizewinners will be honored in an April ceremony.

“The 2021 awards celebrate the diversity of immigrant contributions to biomedical research, to filmmaking, and to society,” Vilcek Foundation President Rick Kinsel said in a press release. “In recognizing foreign-born scientists and dynamic leaders in the arts and in public service, we seek to expand the public dialogue about the intellectual value and artistic diversity that immigration provides the United States.”

Ibrahim Cissé

A faculty member in the departments of Physics and Biology, Ibrahim Cissé received the Vilcek Prize for Creative Promise in Biomedical Science for using super-resolution biological imaging to directly visualize the dynamic nature of gene expression in living cells.

Born in Niger, Cissé assumed he would be a lawyer like his father, but he soon became inspired by the science he saw in American films. His high school did not have a laboratory, so he completed high school two years early, enrolled in an English as a Second Language program at the University of North Carolina at Wilmington, and enrolled in Durham Technical Community College before transferring to North Carolina Central University, a historically Black college that was notable for its undergraduate science and mathematics research programs.

Following graduation, he spent a summer at Princeton University working in condensed matter physics. There, Cissé was confronted by physics professor Paul Chaikin with a question about elliptical geometry and particle density, using M&M’s candies. Cissé’s creative problem-solving enabled him and his fellow researchers to develop experiments for observing and quantifying their results, and they coauthored a paper that was published in Science magazine.

For graduate studies, he was at the University of Illinois at Urbana-Champaign, and earned a PhD under the supervision of single-molecule biophysicist Taekjip Ha, who was leading research in high-resolution, single-biomolecule imaging technology. Cissé’s interest in using physics to understand the physical processes in biology led him to a post-doctoral fellowship at École Normale Supérieure Paris. He showed that RNA polymerase II, a critical protein in gene expression, forms fleeting (“transient”) clusters with similar molecules in order to transcribe DNA into RNA. He joined the Howard Hughes Medical Institute’s Janelia Research Campus as a research specialist in the Transcription Imaging Consortium, before joining the MIT Department of Physics in 2014, and was recently granted tenure and a joint appointment in biology.

The Cissé Laboratory focuses on the development of high-resolution microscopy techniques to examine the behavior of single biomolecules in living cells, and his own research focuses on the process by which DNA gets decoded into RNA. His Time-Correlated Photoactivated Localization Microscopy (tcPALM) technique of imaging was able to peer inside living cells to study the dynamics of protein clusters. This discovery has led to breakthroughs in viewing the clustering and droplet-like behavior of RNA polymerase II during RNA transcription. In an interview with MIT News, he stated, “It’s becoming clearer that physics may be just as important as biology for understanding how cells work.”

Other national and international awards include the Young Fluorescence Investigator Award from the American Biophysical Society, the Pew Biomedical Scholars, and the National Institute of Health Director’s New Innovator Award. He is a Next Einstein Forum fellow and was listed in Science News’ Scientists to Watch.

Ruth Lehmann

Professor of biology and director of Whitehead Institute for Biomedical Research Ruth Lehmann received the Vilcek Prize in Biomedical Science. As a developmental and cell biologist, she investigates the biology of germ cells, which give rise to sperm and eggs.

The daughter of a teacher and an engineer, Lehmann was captivated by science from a young age. She grew up in Cologne, Germany, and majored in biology as an undergraduate at the University of Tübingen. Her Fulbright Fellowship in 1977 brought her to the University of Washington in Seattle, and served as the catalyst that spurred her career using fruit flies to understand germ cell biology. She went on to train with renowned fruit fly geneticists Gerold Schubiger and Jose Campos-Ortega, learning classical developmental biology and electron microscopy techniques. She then performed her doctoral research with future Nobel laureate Christiane Nüsslein-Volhard at the Max Planck Institute for Developmental Genetics. There, Lehmann probed the maternal genes that influence fruit fly embryo development — studies that ignited her fervor for germ cell research. Later, as a postdoc at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England, she worked with Michael Wilcox and Peter Lawrence to pinpoint the molecules that control the fate of these vital cells.

Lehmann arrived at MIT in 1988, where she served as a professor and member of the Whitehead Institute for eight years. “Being an immigrant in the United States was exhilarating,” she says, “because of the openness to new ideas and the encouragement to take risks and be creative.”

She was recruited to the Skirball Institute at New York University (NYU), where she was appointed as the institute’s director, as well as the director of the Helen and Martin Kimmel Center for Stem Cell Biology, and chair of the Department of Cell Biology at NYU’s Langone Medical Center.

Lehmann returned to MIT this summer to launch the Lehmann Lab and become director of the Whitehead Institute in July.

Although she began her career focused on the formation and maintenance of germ cells, Lehmann has since revealed key insights into their migration — and more recently into mitochondrial inheritance. Her influential work regarding the development and behavior of these essential cells has also enriched related fields including stem cell biology, lipid biology, and DNA repair.

“It means so much to me to be recognized as an immigrant and a researcher,” says Lehmann. “In these days, immigrants don’t feel as welcomed as I did when I came to this country. For me, coming to the U.S. meant to be given a chance to live the dream of being a scientist. This allowed me to explore the fascinating biology of the germ line together with a group of incredibly talented trainees and staff, many of them immigrants themselves, and I share this wonderful recognition with them.”

Lehmann’s accolades include membership to the National Academy of Sciences, American Academy of Arts and Sciences, and European Molecular Biology Organization, as well as the Conklin Medal from the Society for Developmental Biology, the Porter Award from the American Society for Cell Biology, and the Lifetime Achievement Award from the German Society for Developmental Biology.

Silvi Rouskin

The Andria and Paul Heafy Whitehead Fellow at the Whitehead Institute, Silvi Rouskin received the Vilcek Prize for Creative Promise in Biomedical Science for developing methods to unravel the shapes of RNA molecules inside cells — aiding the potential development of RNA-based therapeutics.

The daughter of rock musicians in early-1980s communist Bulgaria, she grew up fascinated with the geometry of the flora and fauna around her. At 10, she started saving her lunch money to buy a miniature telescope. At 15 she knew that her best chances to study science would be in the United States, and so she joined a student exchange program in Idaho.

“I was not only allowed but encouraged to question my superiors,” she recalls. “I felt free to speak my mind, and often debated with my teachers.” Rouskin completed her GED and studied physics and biochemistry at the Florida Institute of Technology at 16.

As a staff research associate in the laboratory of Joseph DeRisi at the University of California at San Francisco, Rouskin first began studying RNA, using microarrays to detect and track viral infection. She opted to stay at UCSF to pursue her PhD in biochemistry and molecular biology.

She joined the Whitehead Institute in 2015, and established the Rouskin Lab to focus on the structure of RNA molecules, including viruses, and to determine how structure influences RNA processing and gene expression in HIV-1 and other viruses. Most recently, Rouskin uncovered the higher-order structure of the RNA genome of SARS-CoV2 — the virus that causes Covid-19  — in infected cells at high resolution.

“The goal of my own lab has been to perform basic RNA research with clear therapeutic applications and a particular focus on the vulnerabilities of RNA viruses,” says Rouskin. “I want my research to matter for medicine, and so I always approach my research with a cognizance of how my work can directly benefit people.”

Rouskin has also received the Harold M. Weintraub Graduate Student Award for outstanding achievements in biological sciences and the Burroughs Wellcome Fund Career Award at the Scientific Interface.